Clinical Trials on Vaccine Response in Finland

Total 82 results

Lars Rombo

Completed

Hepatitis A Vaccine in Patients With Immunomodulating Drugs

Response to Hepatitis A Vaccine

Finland, Sweden
Pfizer

Completed

Study to Evaluate the Safety and Immunogenicity of Nimenrix (Registered) in Healthy Infants, Given at 3 and 12 Months of Age

Meningococcal Vaccine

Finland, Spain, Poland
Helsinki University Central Hospital
University of Helsinki

Recruiting

Immune Response Elicited by Concomitant Administration of Oral Typhoid Fever (Vivotif®) and Cholera (Dukoral®) Vaccines

Cholera | Typhoid Fever | Vaccine-Preventable Diseases

Finland
Helsinki University Central Hospital

Unknown

PCV13 + Hepatitis A Vaccine for Adults (PCV13+HepA)

Measurement of Immune Response to Prevenar13 | Measurement of Immune Response to Hepatitis A

Finland, Sweden
Helsinki University Central Hospital

Completed

Assessment of Fluid Responsiveness by Elevation of PEEP in Patients With Septic Shock

Septic Shock

Finland
Pfizer

Completed

A Trial To Assess The Safety, Tolerability, And Immunogenicity Of Rlp2086 Vaccine When Administered In Either 2- Or 3-Dose Regimens In Healthy Subjects Aged ≥11 To <19 Years

Meningococcal Vaccine

Spain, Germany, Finland, Czechia, Poland, Denmark, Sweden
Pfizer

Completed

A Trial to Describe the Immunogenicity and Safety of 2 Doses of Bivalent rLP2086 (Trumenba) and a Pentavalent Meningococcal Vaccine in Healthy Subjects >=10 to <26 Years of Age.

Meningococcal Vaccine

United States, Finland, Czechia, Poland
Pfizer

Completed

A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 Years

Meningococcal Vaccine

United States, Canada, Finland, Italy, Poland, United Kingdom, Czech Republic, Germany
IDeA States Pediatric Clinical Trials Network
National Institutes of Health (NIH); University of Nebraska; University of Montana

Active, not recruiting

Improving Pediatric COVID-19 Vaccine Uptake Using an mHealth Tool (MoVeUP)

Telemedicine | Pediatric ALL | Vaccine Hesitancy | COVID-19 Vaccines

United States
Helsinki University Central Hospital
University Hospital Inselspital, Berne

Completed

Targeted Tissue Perfusion Versus Macrocirculatory-guided Standard Care in Patients With Septic Shock (TARTARE-2S)

Critical Illness | Shock; Septic

Finland, Switzerland
Herlev Hospital

Completed

Lactic Acid in the Rectum and Life-Threatening Infection

Septic Shock

Denmark, Finland
Kuopio University Hospital

Completed

Neutropenic Fever, Inflammatory Markers and Sepsis in Haematological Patients

Sepsis

Finland
Turku University Hospital
University of Turku

Recruiting

Safety and Efficacy of HA380 Hemoadsorption in Patients With Septic Shock (HEMOX-HDF)

Septic Shock | Acute Kidney Injury

Finland
Vaxcyte, Inc.

Completed

Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Adults

Pneumococcal Vaccines

United States
Alteco Medical AB
Uppsala University; TFS Trial Form Support

Terminated

ASSET - a Double-Blind, Randomized Placebo-Controlled Clinical Investigation With Alteco® LPS Adsorber (ASSET)

Septic Shock

Finland, Norway, Sweden
University of Helsinki

Completed

Combination Therapy With Fluoroquinolone in Staphylococcus Aureus Bacteremia (FINLEVO)

Sepsis | Bacteremia | Staphylococcus Aureus | Endocarditis

Finland
Pfizer

Completed

A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to Gardasil and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 11 and 17

Vaccines | Meningococcal Vaccines

United States
Pfizer

Completed

A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to MCV4, Tdap and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 10 Through 12 Years of Age

Vaccines | Meningococcal Vaccines

United States
Vaxcyte, Inc.

Active, not recruiting

Safety, Tolerability, and Immunogenicity Study of a 31-Valent Pneumococcal Conjugate Vaccine (VAX-31) in Adults

Pneumococcal Vaccines

United States
Anders Perner

Completed

Conservative vs. Liberal Approach to Fluid Therapy of Septic Shock in Intensive Care (CLASSIC)

Sepsis | Septic Shock

Denmark, Finland
Thrombologic ApS
Rigshospitalet, Denmark; Anders Perner

Terminated

Integrilin and Ilomedin in Combination in Comparison to Standard Treatment in Severe Pneumonia Patients With Severe Sepsis

Pneumonia

Finland, Denmark
Pfizer

Completed

A Trial to Assess the Safety, Tolerability and Immunogenicity of Repevax and rLP2086 Vaccine When Given Together in Healthy Subjects Aged >=11 to <19 Years.

Meningitis | Meningococcal Vaccine | rLP2086 | Repevax | N Meningitidis Serogroup B

Germany, Finland, Poland
Turku University Hospital
Mead Johnson Nutrition; Academy of Finland

Completed

Lactobacillus Rhamnosus GG: Interaction With Human Microbiota and Immunity

Gut Microbiota | Skin Microbiota | Humoral Immune Responses | Severity of Atopic Dermatitis

Finland
Immunexpress
Rhode Island Hospital

Terminated

The Ward Study for SeptiCyte® Lab to Distinguish Between Infection-positive and Infection-negative SIRS

Sepsis | SIRS

United States
Rhode Island Hospital

Recruiting

Assessment for Implementation Methods in Sepsis (AIMS)

Septic Shock | Sepsis Severe

United States
The Miriam Hospital

Recruiting

De-resuscitation Informed by Ultrasound for Patients With Sepsis (DRI-US)

Sepsis | Septic Shock | Sepsis, Severe | Volume Overload

United States
Tufts Medical Center
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Recruiting

Salivary Profiling in Infants Treated for Suspected Sepsis: The SPITSS Study (SPITSS)

Infection; Newborn

United States
Rhode Island Hospital

Completed

Restrictive Intravenous Fluids Trial in Sepsis (RIFTS)

Septic Shock | Severe Sepsis

United States
Abionic SA
Avania

Completed

Evaluation of Immunoassay Measurements of Pancreatic Stone Protein Performed on abioSCOPE® Device With the PSP Assay on ICU Patients at Risk of Sepsis as an Aid in Identifying Sepsis

Sepsis

United States
T2 Biosystems

Completed

T2Bacteria Panel Pivotal Study (T2Bacteria)

Bacteremia

United States
Scandinavian Critical Care Trials Group
Rigshospitalet, Denmark; University of Copenhagen; Copenhagen Trial Unit, Center...

Completed

Transfusion-requirements in Septic Shock Trial (TRISS)

Septic Shock

Sweden, Norway, Finland, Denmark
T2 Biosystems

Completed

Serial Therapeutic and Antifungal Monitoring Protocol (STAMP)

Candidemia

United States
University Medicine Greifswald
European Society of Intensive Care Medicine; Becton, Dickinson and Company; European... and other collaborators

Completed

European Sepsis Care Survey

Sepsis

Netherlands, Norway, Belgium, Czechia, Denmark, Finland, France, Germany, Greece, Israel, Italy, Moldova, Republic of, Poland, Portugal, Romania, Russian Federation, Spain, Sweden, Turkey, United Kingdom
Brown University

Recruiting

Using Telehealth to Address Alcohol Misuse in HIV Care (ReACH3)

Alcohol Drinking | HIV Viremia

United States
Biosite

Withdrawn

Multi-marker INDex for the Risk Assessment of Sepsis in the Emergency departmenT (MINDSET) (MINDSET)

Sepsis

United States
Anders Perner
Rigshospitalet, Denmark; University of Copenhagen; B. Braun Melsungen AG; Copenhagen...

Completed

Scandinavian Starch for Severe Sepsis/Septic Shock Trial (6S)

Septic Shock | Severe Sepsis

Denmark, Norway, Finland, Iceland
Inotrem

Active, not recruiting

Efficacy, Safety and Tolerability of Nangibotide in Patients With Septic Shock (ASTONISH)

Shock, Septic

Belgium, France, Spain, Denmark, Finland, Ireland
Cheetah Medical Inc.

Completed

Cardiac Output Monitoring Managing Intravenous Therapy (COMMIT) to Treat Emergency Department Severe Sepsis (COMMIT)

Sepsis

United States
GlaxoSmithKline

Completed

Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks

Infections, Rotavirus | Rotavirus Vaccines

United States, Finland, Germany, Taiwan, Spain, Costa Rica, Korea, Republic of, Japan
GlaxoSmithKline

Completed

Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age

Infections, Papillomavirus | Papillomavirus Vaccines

United States
Belinda Howe
Australian and New Zealand Intensive Care Society Clinical Trials Group; Australasian...

Unknown

Australasian Resuscitation In Sepsis Evaluation Randomised Controlled Trial (ARISE)

Severe Sepsis

New Zealand, Australia, Finland, Ireland, Hong Kong
Children's Hospital of Philadelphia
M.D. Anderson Cancer Center; The Hospital for Sick Children; Eunice Kennedy Shriver... and other collaborators

Recruiting

Pragmatic Pediatric Trial of Balanced Versus Normal Saline Fluid in Sepsis (PRoMPT BOLUS)

Shock | Septic

United States
VBI Vaccines Inc.

Completed

Immunogenicity and Safety of Sci-B-Vac® to Engerix-B® in Adults

Hepatitis B Vaccines

United States, Canada, Finland, Belgium
VBI Vaccines Inc.

Completed

Lot-to-lot Consistency of Sci-B-Vac™ in Adults

Hepatitis B Vaccines

United States, United Kingdom, Finland, Belgium, Canada, Germany
Cheetah Medical Inc.

Completed

Fluid Responsiveness Evaluation in Sepsis-associated Hypotension (FRESH)

Sepsis | Hypotension

United States, United Kingdom
Eli Lilly and Company

Completed

Evaluate Protein C Levels in Severe Sepsis Patients on Drotrecogin Alfa (Activated)

Severe Sepsis

United States, Belgium, Spain, France, Finland, Germany, Canada, United Kingdom, Puerto Rico
Eli Lilly and Company

Completed

The Study of Drotrecogin Alfa (Activated) in Adult Patients With Severe Sepsis at a Low Risk of Death

Sepsis

Canada, Finland, Belgium, Argentina, Chile, Australia, Austria, Brazil, Czech Republic, Denmark, Egypt, France
Agennix

Completed

Safety and Efficacy Study of Recombinant Human Lactoferrin to Treat Severe Sepsis

Severe Sepsis

United States, Canada, France, Germany, Spain
AstraZeneca

Completed

A Study to Compare the Efficacy and Safety of 2 Dosing Regimens of IV Infusions of AZD9773 (CytoFab™) With Placebo in Adult Patients With Severe Sepsis and/or Septic Shock

Septic Shock | Severe Sepsis

Czech Republic, France, Spain, Finland, Canada, Australia, Belgium
Bavarian Nordic

Completed

A Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-naïve Subjects

Smallpox

United States

Clinical Trials on Vaccine Response in Finland

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bahamas

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations